Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P12883
UPID:
MYH7_HUMAN
Alternative names:
Myosin heavy chain 7; Myosin heavy chain slow isoform; Myosin heavy chain, cardiac muscle beta isoform
Alternative UPACC:
P12883; A2TDB6; B6D424; Q14836; Q14837; Q14904; Q16579; Q2M1Y6; Q92679; Q9H1D5; Q9UDA2; Q9UMM8
Background:
Myosin-7, known alternatively as Myosin heavy chain 7, Myosin heavy chain slow isoform, and Myosin heavy chain, cardiac muscle beta isoform, plays a pivotal role in muscle contraction. It is an actin-based motor molecule with ATPase activity, essential for the contraction of skeletal and cardiac muscle by forming bipolar thick filaments.
Therapeutic significance:
Myosin-7 is implicated in several hereditary disorders, including familial hypertrophic cardiomyopathy, dilated cardiomyopathy, congenital myopathies, and left ventricular non-compaction. These conditions highlight the protein's critical role in cardiac and skeletal muscle function, suggesting that targeting Myosin-7 could lead to novel treatments for these debilitating diseases.